Seeking Alpha

Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting

The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
Seeking Alpha

Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Business Wire

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...

RG-6299 Sales Forecast, and Market Size Analysis - 2034 Released — Examines Mechanism, Dosing, Pricing, Patents, and Emerging Competitors

RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, ...

Novartis Pharma AG: Novartis Fabhalta (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...